New hope for kids with rare swelling disorder: sebetralstat shows promise
NCT ID NCT06467084
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a drug called sebetralstat in 36 children aged 2 to 11 with hereditary angioedema (HAE) types I or II, a condition that causes sudden, painful swelling. The goal was to see if the drug is safe and how well it works to relieve attacks. The trial was open-label, meaning everyone knew they were getting the drug, and it has already been completed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sebetralstat (KVD900)
What this could lead to
If it works, this could provide a fast-acting treatment option for children with hereditary angioedema to relieve swelling attacks.
What could go wrong
This was a small, open-label study with no placebo group, so results may be less reliable. Side effects are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
KalVista Investigative Site
Birmingham, Alabama, 35209, United States
-
KalVista Investigative Site
Scottsdale, Arizona, 85251, United States
-
KalVista Investigative Site
San Diego, California, 92123, United States
-
KalVista Investigative Site
Santa Monica, California, 90404, United States
-
KalVista Investigative Site
Evansville, Indiana, 47715, United States
-
KalVista Investigative Site
Wheaton, Maryland, 20902, United States
-
KalVista Investigative Site
St Louis, Missouri, 63141, United States
-
KalVista Investigative Site
Toledo, Ohio, 43560, United States
-
KalVista Investigative Site
Hershey, Pennsylvania, 17011, United States
-
KalVista Investigative Site
Dallas, Texas, 75231, United States
-
KalVista Investigative Site
Edmonton, Alberta, T6G 2B7, Canada
-
KalVista Investigative Site
Lille, 59000, France
-
KalVista Investigative Site
Marseille, 13005, France
-
KalVista Investigative Site
Paris, 75012, France
-
KalVista Investigative Site
Frankfurt am Main, 60590, Germany
-
KalVista Investigative Site
Frankfurt am Main, 60596, Germany
-
KalVista Investigative Site
Haifa, 31048, Israel
-
KalVista Investigative Site
Petah Tikva, 4920235, Israel
-
KalVista Investigative Site
Tel Aviv, 6423906, Israel
-
KalVista Investigative Site
Milan, 20097, Italy
-
KalVista Investigative Site
Padova, 35128, Italy
-
KalVista Investigative Site
Rome, 00133, Italy
-
KalVista Investigative Site
Kawagoe, 350-8550, Japan
-
KalVista Investigative Site
Tokyo, 113-8431, Japan